References
1. Silva C, et al. Cost-Effectiveness of Erenumab for the Prevention of Migraine in Portugal. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND56, 16 Nov 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2020-3282/106684
2. Silva C, et al. Calculator Tool to Estimate the Economic Burden of Migraine and IMPACT Scenarios of Erenumab in the NHS Portuguese Hospitals. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND48, 16 Nov 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2020-3282/105906
Rights and permissions
About this article
Cite this article
Erenumab cost-effective option for migraine prevention in Portugal. PharmacoEcon Outcomes News 868, 15 (2020). https://doi.org/10.1007/s40274-020-7347-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7347-7